FMTX News and Press, Forma Therapeutics Holdings Inc. From 07/12/22

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that its Board of Directors granted to Agustín Melián, M.D. and Linea A...

Agustín Melián, M.D. to be named Executive Vice President, Head of Research and Development and Linea Aspesi to be named Senior Vice President, Chief Human Resources Officer Appointments position Forma for the next phase of growth in late-stage global development...

Updated results from the completed Phase 1 study of etavopivat in patients with sickle cell disease (SCD) Study design for the Phase 2 Gladiolus Study of etavopivat in patients with transfusion-dependent (TD) SCD or non-TD/TD thalassemia Forma Therapeutics Holdings...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will participate in the Jefferies Healthcare Conference taking place ...

Expanding etavopivat development in 2022 with Phase II trial exploring transfusion burden across sickle cell disease (SCD), thalassemia and myelodysplastic syndromes (MDS) Phase 1 trial of FT-7051 in mCRPC proceeding with predicted efficacious dose range under evaluation and e...

Forma Therapeutics Holdings Inc. (FMTX) Q1 2022 Earnings Conference Call May 6, 2022, 8:00 AM ET Company Participants Frank Lee – President and Chief Executive Officer Mario Corso – Senior Director Investor Relations Patrick Kelly – Chief Medical Officer Dave Cook –...

Gainers: ChemoCentryx (CCXI) +19%. iRhythm Technologies (IRTC) +16%. Jounce Therapeutics (JNCE) +15%. Grifols (GRFS) +9%. Sensus Healthcare (SRTS) +8%. Losers: Joint (JYNT) -46%. Endo International (ENDP) -34%. Guardant Health (GH) -26%. Gain ...

Forma Therapeutics press release (NASDAQ:FMTX): Q1 GAAP EPS of -$0.93 beats by $0.15. Cash and cash equivalents of $441.35M For further details see: Forma Therapeutics GAAP EPS of -$0.93 beats by $0.15

Clinical programs advancing in rare hematologic diseases and cancers May 26 R&D Day to focus on research pipeline strategy and expanded development programs Cash balance of $441.3 million positions company with runway through the third quarter of 2024 F...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release first quarter 2022 financial results Friday, May 6, 2022...